`
`CENTER FOR DRUG EVALUATION AND
`RESEARCH
`RESEARCH
`
`
`
`
`
`
`APPLICATION NUMBER:
`22-228
`
`
`
`APPLICA TI0N NUMBER:
`
`OTHER REVIEW(S)
`OTHER REVIEW! S!
`
`
`
`
`
`22-228
`
`
`
`Food and Drug Administration
`Center for Drug Evaluation and Research
`Division of Drug Marketing, Advertising, and Communications
`
`
`Memorandum
`***Pre-Decisional Agency Information ***
`
`
`Date:
`
`To:
`
`
`
`
`
`
`
`From:
`
`
`
`August 14, 2009
`
`Raphael Rodriguez
`Regulatory Health Project Manager
`Division of Anti-Infective and Ophthalmology Products
`
`Beth Carr, Pharm.D., Regulatory Review Officer
`Lynn Panholzer, Pharm.D., Regulatory Review Officer
`Division of Drug Marketing, Advertising, and Communications
`(DDMAC)
`
`Bepreve ™ (bepotastine besilate ophthalmic solution) 1.5%
`NDA: 22-288
`
`
`Subject:
`
`
`
`DDMAC has reviewed the proposed product labeling for Bepreve ™ (bepotastine
`besilate ophthalmic solution) 1.5% (Bepreve) submitted by Wiley Chambers via
`email on August 14, 2009 (attached); and we offer the following comments.
`Please feel free to contact me at (301) 796-3674 with any questions or
`clarifications.
`
`
`Package Insert
`
`HIGHLIGHTS OF PRESCRIBING INFORMATION
`
`
`WARNINGS AND PRECAUTIONS
`
`
`
`•
`
`“Remove contact lenses prior to instillation of Bepreve.”
`
`
`For clarification purposes, we recommend adding the sentence, “Lenses may be
`reinserted after 10 minutes following administration of Bepreve,” to the above
`Warning and Precaution.
`
`FULL PRESCRIBING INFORMATION
`
` 6
`
`
`
`ADVERSE REACTIONS
`
`
`In accordance with the January 2006 Guidance for Industry: Adverse Reactions
`Section of the Label for Human Prescription Drugs and Biologics – Content and
`Format, please include the following:
`
`
`
`Bepreve (bepotastine besilate ophthalmic solution)
`NDA 22-288
`
`
`2
`
` Please include an adequate description of the data sources for the
`adverse event data, as outlined in the guidance. For example, please
`include information on whether the trials were double blinded, randomized,
`and placebo controlled trials, if available. Also, please include the dosage,
`frequency, and duration of therapy that patients received.
`
` •
`
`
`
`•
`
`Identify adverse reactions, if any, that resulted in a significant rate of
`discontinuation or other clinical intervention (e.g., dosage adjustment,
`need for other therapy to treat an adverse reaction) in clinical trials.
`
`CLINICAL STUDIES
`
`
`14
`
`The description of the clinical studies is vague and may be used by the sponsor
`to promote in a misleading manner. We suggest rewriting this section with the
`following information: number of patients studied in each arm of the trial, age
`ranges of the patients, major study endpoints, descriptions of the measurement
`tools used to evaluate the outcomes (the measurable signs of ocular itching),
`actual results (tabular format), and any appropriate accompanying statistics.
`
`We recommend that specific efficacy data be included to qualify the superiority
`claims made in the label. Broad claims about the superiority of the drug versus
`vehicle without the context of the actual data may be used to misleadingly
`overstate the efficacy of the drug in promotional materials.
`
`
`•
`
`“Bepreve (bepotastine besilate ophthalmic solution) 1.5% was more
`effective than its vehicle for relieving ocular itching induced by an ocular
`allergen challenge, both at CAC 15 minutes post-dosing and a CAC 8
`hours post dosing of Bepreve.”
`
`
`This claim is very vague and may be used promotionally to overstate the efficacy
`of Bepreve. Specifically, it does not identify the specific endpoint(s) that were
`measured. We recommend that the claim be revised to specify the measure of
`relief from ocular itching to which the claim refers.
`
`
`
`
`
`---------------------------------------------------------------------------------------------------------
`This is a representation of an electronic record that was signed
`electronically and this page is the manifestation of the electronic
`signature.
`---------------------------------------------------------------------------------------------------------
`/s/
`----------------------------------------------------
`
`BETH M CARR
`08/27/2009
`
`
`
`Department of Health and Human Services
`Public Health Service
`Food and Drug Administration
`Center for Drug Evaluation and Research
`Office of Surveillance and Epidemiology
`
`
`
`July 28, 2009
`Wiley Chambers, M.D., Acting Director
`Division of Anti-Infective & Ophthalmology Products
`Laura Pincock, Pharm.D., Acting Team Leader
`Denise Toyer, Pharm.D., Deputy Director
`Carol Holquist, R.Ph., Director
`Division of Medication Error Prevention and Analysis
`(DMEPA)
`Raichell S. Brown, Pharm.D., J.D., Safety Evaluator
`Division of Medication Error Prevention and Analysis
`(DMEPA)
`Label and Labeling Review
`Bepreve (Bepotastine Besilate Ophthalmic Solution) 1.5%
`NDA # 22-288
`ISTA Pharmaceuticals
`2008-1998
`
`Date:
`To:
`
`Through:
`
`From:
`
`Subject:
`Drug Name(s):
`Application Type/Number:
`Applicant/sponsor:
`OSE RCM #:
`
`
`
`
`
`
`
`
`
`
` 1
`
`
`INTRODUCTION
`This review is in response to a request from the Division of Anti-Infective & Ophthalmology
`Products on December 15, 2008 to evaluate the labels and labeling of Bepreve (Bepotastine
`Besilate Ophthalmic Solution) 1.5% for the potential to contribute to medication errors. The
`Applicant submitted container labels, carton labeling, and insert labeling on February 16, 2009.
`The Division of Medication Error Prevention and Analysis also completed a Proprietary Name
`Review of Bepreve (See OSE Review #2008-1987 dated February 6, 2009).
`
`2 METHODS AND MATERIALS
`DMEPA used Failure Mode and Effects Analysis (FMEA) in our evaluation of the
`container labels, carton labeling, and insert labeling submitted on February 6, 2009
`(See Appendices A through H).
`
`3 RECOMMENDATIONS
`Our evaluation noted areas where information on the container labels, carton labeling,
`and insert labeling can be improved to minimize the potential for medication errors. We
`provide recommendations on the insert labeling in Section 3.1 Comments to the Division
`for discussion during the review team’s label and labeling meetings. Section 3.2
`Comments to the Applicant contains our recommendations for the container label and
`carton labeling. We request the recommendations in Section 3.2 be communicated to the
`Applicant prior to approval.
`We are willing to meet with the Division for further discussion, if needed. Please copy
`the Division of Medication Error Prevention and Analysis (DMEPA) on any
`communication to the Applicant with regard to this review. If you have further questions
`or need clarifications, please contact Darrell Jenkins, OSE Regulatory Project Manager,
`at 301-796-0558.
`
`
`
`
`
`1
`
`
`
`
`
`3.1 COMMENTS TO THE DIVISION
`
`Based on our assessment of the insert labeling, we recommend that the Applicant
`implement the following revisions:
`
`1.
`
`Remove the trailing zero after the decimal point in the net quantity
`statements in the insert labeling.
`1 mL (not 1.0 mL)
`5 mL (not 5.0 mL)
`10 mL (not 10.0 mL)
`DMEPA, consistent with recommendations from the Institute of Safe
`Medication Practices (ISMP) and National Coordinating Council for
`Medication Error Reporting and Prevention (NCC MERP), advises against
`the use of trailing zeros because they are error-prone and can result in ten-
`fold misinterpretation if the decimal is not seen.
`
`2.
`
`Revise the statement in the DOSAGE AND ADMINISTRATION section that
`currently reads,
`
` to read
`
`
`
`
`
`Instill one drop of Bepreve into the affected eye(s) twice a day.
`
`Use of the phrases, ‘For relief within 3 minutes’ and ‘for relief lasting up
`to 8 hours’ may create the impression that this product should be used on
`an as needed basis. In addition, use of the phrase ‘for relief lasting at least
`8 hours’ may lead to the inappropriate dosing of Bepreve every 8 hours.
`
`3.
`
`Add or relocate the following statement, currently located in the
`WARNINGS AND PRECAUTIONS section, to the DOSAGE AND
`ADMINISTRATION section of the insert labeling because it is necessary for
`the proper administration of the product by patients who wear contact
`lenses.
`Remove contact lenses prior to installation of Bepreve.
`Lenses may be reinserted after 10 minutes following
`administration of Bepreve.
`
`
`
`
`
`
`
`2
`
`(b) (4)
`
`
`
`
`
`3.2 COMMENTS TO THE APPLICANT
`We have evaluated your container labels and carton labeling for Bepreve (Bepotastine
`Besilate Ophthalmic Solution) 1.5%. Please revise your container labels and carton
`labeling as follows:
`1.
`Container Labels and Carton Labeling:
`a. Remove the trailing zero located after the decimal point in the net quantity
`statements. For example,
`
`1 mL (not 1.0 mL)
`5 mL (not 5.0 mL)
`10 mL (not 10.0 mL)
`DMEPA, consistent with recommendations from the Institute of
`Safe Medication Practices (ISMP) and National Coordinating
`Council for Medication Error Reporting and Prevention (NCC
`MERP), advises against the use of trailing zeros because they are
`error-prone and can result in ten-fold misinterpretation if the
`decimal is not seen.
`b. Increase the prominence of the established name, while ensuring that the
`prominence of the dosage form remains commensurate to that of the
`established name.
`According to 21 C.F.R. §201.10(g)(2), required statement on a
`label can lack appropriate prominence by reason of the “style of
`type” in which the statement appears or “crowding” of the words
`within the statement. The statement “bepotastine besilate
`ophthalmic solution” lacks appropriate prominence because of one
`or both of these reasons.
`c. Relocate the route of administration statement to the principle display
`panel. Presentation of the route of administration on the principle display
`panels is customary and, thereby, fosters greater comprehension of the
`information by enhancing its clarity and ease of access. (See 21 C.F.R.
`201.15(a)(1)).
`Container Labels:
`a. Add the designation “Expiration Date,” or a similarly appropriate
`designation, to the side or back panel of the container label.
`b. Add the designation “Lot number,” or a similarly appropriate designation,
`to the side or back panel of the container label coupled with the expiration
`date designation as it appears on the carton labeling.
`
`2.
`
`
`
`
`
`3
`
`
`
`
`
`3.
`
`Carton Labeling:
`Relocate the net quantity statement away from the statement of strength on
`the carton labeling to decrease the potential for confusion between the
`numerical statements. DMEPA notes that the Applicant has separated the
`net quantity and statement of strength on the container labels; similar
`positioning could be used on the carton labeling.
`
`
`APPENDICES
`Appendix A: Container Label for 1 mL (Professional Sample)
`
`
`
`
`
`
`
`
`4
`
`7 Page(s) have been Withheld in Full following this page as B4 (TS)
`
`(b) (4)
`
`
`
`---------------------------------------------------------------------------------------------------------
`This is a representation of an electronic record that was signed
`electronically and this page is the manifestation of the electronic
`signature.
`---------------------------------------------------------------------------------------------------------
`/s/
`----------------------------------------------------
`
`RAICHELL S Brown
`07/28/2009
`
`LAURA L PINCOCK
`07/28/2009
`
`DENISE P TOYER
`07/29/2009
`
`CAROL A HOLQUIST
`07/29/2009
`
`